Interestingly, most proteins associated with outcome followed a trajectory differing from more well-studied stroke outcome blood biomarkers, e.g. copeptin and NfL, as levels were generally lower in the acute stroke phase, and as lower acute and 3-month levels were associated with less favorable outcome. This evidence concerns the gene NEFL and stroke disorder.